93514-81-9

Upstream product

• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 121-50-6 3-amino-4-chlorobenzotrifluoride 

Downstream Products

• 1350805-17-2 C₁₈H₁₁F₆N₃O₂ 
• 1350805-16-1 C₂₄H₂₁F₆N₃O₃ 
• 1350805-15-0 C₂₄H₁₉F₆N₃O₄ 
• 1350805-14-9 C₂₄H₁₉F₆N₃O₄ 
• 1350805-13-8 C₂₄H₂₁F₆N₃O₄ 
• 641993-18-2 8-chloro-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxylic acid 
• 1159590-65-4 ethyl 4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxylate 
• 64-17-5 ethanol 
• 1221573-17-6 ethyl 8-chloro-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxylate 

Relevant academic research and scientific papers

PROCESSES FOR PRODUCING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention relates to the process for producing modulators of cystic fibrosis transmembrane conductance regulator (CFTR).

SOLID FORMS OF N-(4-(7-AZABICYCLO[2.2.1]HEPTAN-7-YL)-2-TRIFLUOROMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE

The present invention relates to substantially crystalline and solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide (Form A-HCl, Form B, Form B-HCl, or any combination of these forms), pharmaceutical compositions thereof, and methods of treatment therewith.

PROCESS FOR PREPARING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention relates to processes for preparing solid state forms of N-(4-(7-azabicyclo[2.2. 1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, including Compound 1 Form A, Compound 1 Form A- HCl, Compound 1 Form B, and Compound 1 Form B-HCl, any combination of these forms, pharmaceutical compositions thereof, and methods of treatment therewith.

SOLID FORMS OF N-(4-(7-AZABICYCLO[2.2.1]HEPTAN-7-YL)-2-(TRIFLUOROMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE

The present invention relates to solid state forms, for example, crystalline forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, pharmaceutical compositions thereof, and methods therewith.

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator ( CFTR ), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR.

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator ("CFTR"), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR (Formula I) or pharmaceutically acceptable salts thereof, wherein: ring A is selected from: (a), (b), (c), (d), wherein: R1 is -CH3 -CF3 or -CN; R2 is hydrogen, -CH3, -CF3, -OH, or -CH2OH; R3 is hydrogen, -CH3, -OCH3, or -CN; provided that both R2 and R3 are not simultaneously hydrogen; and one of X and Y is nitrogen and the other is carbon.